INT92383

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.65
First Reported 2000
Last Reported 2010
Negated 3
Speculated 0
Reported most in Body
Documents 38
Total Number 38
Disease Relevance 32.94
Pain Relevance 1.32

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (KRAS) mitochondrion (KRAS) plasma membrane (KRAS)
GTPase activity (KRAS)
Anatomy Link Frequency
astrocytes 3
microglia 3
colon 2
macrophages 1
monocytes 1
KRAS (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 98 99.24 Very High Very High Very High
cytokine 102 98.48 Very High Very High Very High
Neurobehavioral 49 90.68 High High
cINOD 7 84.44 Quite High
agonist 34 83.04 Quite High
chemokine 52 79.44 Quite High
Chronic pancreatitis 1 68.52 Quite High
alcohol 4 65.20 Quite High
antagonist 15 58.04 Quite High
palliative 16 58.00 Quite High
Disease Link Frequency Relevance Heat
Hepatitis C Virus Infection 1629 100.00 Very High Very High Very High
Microsatellite Instability 108 100.00 Very High Very High Very High
Apoptosis 167 99.92 Very High Very High Very High
Colon Cancer 300 99.88 Very High Very High Very High
Pancreatic Cancer 41 99.84 Very High Very High Very High
Cancer 808 99.44 Very High Very High Very High
INFLAMMATION 125 99.24 Very High Very High Very High
Hyperplasia 38 98.64 Very High Very High Very High
Non-small-cell Lung Cancer 121 97.90 Very High Very High Very High
Infection 413 97.44 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The HCV core and NS3 proteins activate TLR2 on monocytes to induce cytokines in a NF-?
Gene_expression (proteins) of NS3 in monocytes associated with hepatitis c virus infection and cytokine
1) Confidence 0.65 Published 2010 Journal Gastroenterology Research and Practice Section Body Doc Link PMC2995932 Disease Relevance 1.29 Pain Relevance 0.20
An analysis of SBN found that 53% had point mutations in the Ki-ras gene [63] similar to mutations found in CRC[64], and that overall frequencies of Ki-ras and p53 gene mutations are similar in both [63].
Gene_expression (frequencies) of Ki-ras associated with cancer and colon cancer
2) Confidence 0.65 Published 2010 Journal BMC Gastroenterol Section Body Doc Link PMC2949773 Disease Relevance 1.64 Pain Relevance 0.06
Mutations in KRAS
Gene_expression (Mutations) of KRAS
3) Confidence 0.61 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886318 Disease Relevance 0.43 Pain Relevance 0
Recent updates of the two large phase III studies comparing BSC and therapy with cetuximab or panitumumab have confirmed that KRAS analysis presently is the best way to identify patients with the lowest chance to benefit from EGFR-inhibition, as only 1 patient among a total of more than 160 patients with KRAS mutations achieved response to EGFR-inhibition.55,56,67,68
Gene_expression (analysis) of KRAS
4) Confidence 0.61 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886318 Disease Relevance 0.22 Pain Relevance 0
Clinical features of KRAS-mutated benefiting from cetuximab based-treatment
Gene_expression (features) of KRAS
5) Confidence 0.57 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2432064 Disease Relevance 0.65 Pain Relevance 0
KRAS mutations
Gene_expression (mutations) of KRAS
6) Confidence 0.57 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2432064 Disease Relevance 0.49 Pain Relevance 0
In 9 responding patients, 2 had a KRAS mutation (22%), whereas 12 of 23 (52%) nonresponding patients had a KRAS mutation.
Gene_expression (mutation) of KRAS
7) Confidence 0.57 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2432064 Disease Relevance 0.49 Pain Relevance 0
KRAS mutations
Gene_expression (mutations) of KRAS
8) Confidence 0.57 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2432064 Disease Relevance 0.27 Pain Relevance 0
Expression of an activated K-ras oncogene caused cells treated with either sulindac sulfide or sulfone to undergo apoptosis earlier than nontransfected controls.
Gene_expression (Expression) of K-ras oncogene associated with apoptosis
9) Confidence 0.57 Published 2000 Journal Cancer Epidemiol. Biomarkers Prev. Section Abstract Doc Link 11097222 Disease Relevance 0.66 Pain Relevance 0.07
-catenin, KRAS, and MSI are present, with PTEN inactivation occuring in about 50% of the cases.
Gene_expression (present) of KRAS associated with microsatellite instability
10) Confidence 0.53 Published 2010 Journal Obstetrics and Gynecology International Section Body Doc Link PMC2846683 Disease Relevance 1.63 Pain Relevance 0
However, PTEN and KRAS mutations seem to occur earlier, since they were found in simple hyperplasia, partially associated with monoclonality.
Gene_expression (mutations) of KRAS associated with hyperplasia
11) Confidence 0.53 Published 2010 Journal Obstetrics and Gynecology International Section Body Doc Link PMC2846683 Disease Relevance 1.59 Pain Relevance 0
Other molecular alterations such as KRAS and BRAF mutations do not seem to be associated with PPARG methylation, while a correlation with the microsatellite instability status was found (Figure S1) [10].
Gene_expression (mutations) of KRAS associated with microsatellite instability
12) Confidence 0.50 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2997072 Disease Relevance 0.86 Pain Relevance 0
Loss of heterozygosity, BRAF and KRAS mutations and microsatellite instability analysis
Gene_expression (mutations) of KRAS associated with microsatellite instability
13) Confidence 0.50 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2997072 Disease Relevance 0.34 Pain Relevance 0.03
Analysis of KRAS mutations
Gene_expression (mutations) of KRAS
14) Confidence 0.49 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2896958 Disease Relevance 0.10 Pain Relevance 0
No patient had both KRAS and EGFR mutation.
Gene_expression (mutation) of KRAS
15) Confidence 0.43 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721286 Disease Relevance 1.30 Pain Relevance 0.06
Both of these trials also include extensive correlatives evaluating EGFR IHC, EGFR mutation status, EGFR expression by FISH, KRAS mutation status, and also proteomic analysis.
Gene_expression (expression) of KRAS mutation
16) Confidence 0.43 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721286 Disease Relevance 0.33 Pain Relevance 0
Mutant KRAS (found in approximately 15% to 30% of patients with NSCLC) is associated with worse survival in response to EGFR antibodies in colorectal cancers.67–69 In NSCLC, a retrospective analysis of tumor samples from erlotinib or gefitinib sensitive patients revealed that KRAS mutation was associated with resistance to either therapy.70 Clinical data from the FLEX study71 do not support the hypothesis that KRAS mutation status is predictive for cetuximab efficacy when combined with first-line chemotherapy in advanced NSCLC, whereas early acne-like rash of any grade appears to be associated with better outcome in patients treated with cetuximab.72
Gene_expression (mutation) of KRAS associated with exanthema, cancer, non-small-cell lung cancer, acne and colon cancer
17) Confidence 0.41 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886327 Disease Relevance 0.75 Pain Relevance 0
In the last decade, the advancement of molecular biology improved the understanding of the pathogenesis of pancreatic cancer and characterized a number of genes that mutated in pancreatic cancers, such as somatic mutations in genes INK4A(CDKN2A), TP53, DPC4, BRCA1/2, STK11, APC, KRAS and ATM and PALB2 are found in pancreatic cancers [10]–[18].
Gene_expression (found) of KRAS associated with pancreatic cancer
18) Confidence 0.28 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2912284 Disease Relevance 1.36 Pain Relevance 0.07
Recent publications have shown that the KRAS and BRAF mutation status of colon cancer cells influence the expression rates of multiple proliferative as well as apoptotic signaling intermediates (Kikuchi et al, Cancer Res 2009, Oliveira et al, Oncogene 2003, Seruca et al, 2009), including HIF1?
Gene_expression (status) of KRAS in colon associated with cancer, colon cancer and apoptosis
19) Confidence 0.28 Published 2010 Journal BMC Cancer Section Body Doc Link PMC3003660 Disease Relevance 1.71 Pain Relevance 0
0.5 fold of control), while cyclin A1 and KRAS were up-regulated ?
Gene_expression (were) of KRAS
20) Confidence 0.27 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2970545 Disease Relevance 0.08 Pain Relevance 0.07

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox